Glycogen synthase kinase-3 inhibitor as a multi-targeting anti-rheumatoid drug

masaki arioka, Fumi Takahashi-Yanaga

Research output: Contribution to journalReview article

Abstract

Rheumatoid arthritis (RA) is a chronic inflammatory joint disease that causes swelling, bone erosion, and joint disorder. Patients with RA therefore suffer from pain and physiological disability, and have a decreased quality of life. During the progression of RA, many different types of cells and inflammatory factors influence each other with an important role. A better understanding of the pathology of RA should therefore lead to the development of effective anti-rheumatoid drugs, such as the anti-TNFα antibody. Glycogen synthase kinase-3 (GSK-3) is a cytoplasmic serine/threonine protein kinase that is involved in a large number of key cellular processes and is dysregulated in a wide variety of diseases, including inflammation and osteoporosis. The accumulated evidence has suggested that GSK-3 could be involved in multiple steps in the progression of RA. In the present review, the mechanisms of the pathogenesis of RA are summarized, and recent developments and potential new drugs targeting GSK-3 are discussed.

Original languageEnglish
Pages (from-to)207-213
Number of pages7
JournalBiochemical Pharmacology
Volume165
DOIs
Publication statusPublished - Jul 1 2019

Fingerprint

Glycogen Synthase Kinase 3
Rheumatoid Arthritis
Pharmaceutical Preparations
Protein-Serine-Threonine Kinases
Pathology
Swelling
Erosion
Bone
Antibodies
Joint Diseases
Drug Delivery Systems
Osteoporosis
Anti-Idiotypic Antibodies
Joints
Quality of Life
Inflammation
Bone and Bones
Pain

All Science Journal Classification (ASJC) codes

  • Biochemistry
  • Pharmacology

Cite this

Glycogen synthase kinase-3 inhibitor as a multi-targeting anti-rheumatoid drug. / arioka, masaki; Takahashi-Yanaga, Fumi.

In: Biochemical Pharmacology, Vol. 165, 01.07.2019, p. 207-213.

Research output: Contribution to journalReview article

@article{eaab82459fd04c3e9651cb5938642fb8,
title = "Glycogen synthase kinase-3 inhibitor as a multi-targeting anti-rheumatoid drug",
abstract = "Rheumatoid arthritis (RA) is a chronic inflammatory joint disease that causes swelling, bone erosion, and joint disorder. Patients with RA therefore suffer from pain and physiological disability, and have a decreased quality of life. During the progression of RA, many different types of cells and inflammatory factors influence each other with an important role. A better understanding of the pathology of RA should therefore lead to the development of effective anti-rheumatoid drugs, such as the anti-TNFα antibody. Glycogen synthase kinase-3 (GSK-3) is a cytoplasmic serine/threonine protein kinase that is involved in a large number of key cellular processes and is dysregulated in a wide variety of diseases, including inflammation and osteoporosis. The accumulated evidence has suggested that GSK-3 could be involved in multiple steps in the progression of RA. In the present review, the mechanisms of the pathogenesis of RA are summarized, and recent developments and potential new drugs targeting GSK-3 are discussed.",
author = "masaki arioka and Fumi Takahashi-Yanaga",
year = "2019",
month = "7",
day = "1",
doi = "10.1016/j.bcp.2019.02.020",
language = "English",
volume = "165",
pages = "207--213",
journal = "Biochemical Pharmacology",
issn = "0006-2952",
publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - Glycogen synthase kinase-3 inhibitor as a multi-targeting anti-rheumatoid drug

AU - arioka, masaki

AU - Takahashi-Yanaga, Fumi

PY - 2019/7/1

Y1 - 2019/7/1

N2 - Rheumatoid arthritis (RA) is a chronic inflammatory joint disease that causes swelling, bone erosion, and joint disorder. Patients with RA therefore suffer from pain and physiological disability, and have a decreased quality of life. During the progression of RA, many different types of cells and inflammatory factors influence each other with an important role. A better understanding of the pathology of RA should therefore lead to the development of effective anti-rheumatoid drugs, such as the anti-TNFα antibody. Glycogen synthase kinase-3 (GSK-3) is a cytoplasmic serine/threonine protein kinase that is involved in a large number of key cellular processes and is dysregulated in a wide variety of diseases, including inflammation and osteoporosis. The accumulated evidence has suggested that GSK-3 could be involved in multiple steps in the progression of RA. In the present review, the mechanisms of the pathogenesis of RA are summarized, and recent developments and potential new drugs targeting GSK-3 are discussed.

AB - Rheumatoid arthritis (RA) is a chronic inflammatory joint disease that causes swelling, bone erosion, and joint disorder. Patients with RA therefore suffer from pain and physiological disability, and have a decreased quality of life. During the progression of RA, many different types of cells and inflammatory factors influence each other with an important role. A better understanding of the pathology of RA should therefore lead to the development of effective anti-rheumatoid drugs, such as the anti-TNFα antibody. Glycogen synthase kinase-3 (GSK-3) is a cytoplasmic serine/threonine protein kinase that is involved in a large number of key cellular processes and is dysregulated in a wide variety of diseases, including inflammation and osteoporosis. The accumulated evidence has suggested that GSK-3 could be involved in multiple steps in the progression of RA. In the present review, the mechanisms of the pathogenesis of RA are summarized, and recent developments and potential new drugs targeting GSK-3 are discussed.

UR - http://www.scopus.com/inward/record.url?scp=85061801390&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85061801390&partnerID=8YFLogxK

U2 - 10.1016/j.bcp.2019.02.020

DO - 10.1016/j.bcp.2019.02.020

M3 - Review article

VL - 165

SP - 207

EP - 213

JO - Biochemical Pharmacology

JF - Biochemical Pharmacology

SN - 0006-2952

ER -